A closely watched clinical trial has found that an AstraZeneca breast cancer drug did not improve outcomes for patients, a result that researchers say could limit its future use.
AstraZeneca’s breast cancer pill has failed to meet its goals in a major study, according to a post from medical news outlet STAT News. The trial result is being described as a setback that may restrict how widely the medicine can be used
The findings are significant for patients currently being treated for, or assessed for, breast cancer — a disease that affects tens of thousands of people across the UK each year. Treatments that fail to show benefit in clinical trials are typically not recommended for wider use by regulators or prescribing bodies such as the NHS.
According to reporting by STAT News, corroborated by Reuters and Bloomberg, the drug in question is camizestrant (also known as Etcamah), which was evaluated in the SERENA-4 trial among patients with ER-positive, HER2-negative advanced breast cancer. STAT News covers pharmaceutical and medical research globally.
If you have concerns about a breast cancer diagnosis or ongoing treatment, speak to your GP or specialist team in the first instance. Do not stop or change any prescribed medication without medical advice.
NHS 111 is available 24 hours a day, seven days a week, by phone or online, for health questions that cannot wait for a GP appointment. In an emergency, call 999.
Source: @statnews